Dopamine D3 Receptor Occupancy in Bipolar Depression by Cariprazine (Vraylar): Evaluating Its Antidepressant Benefit
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Cariprazine (Primary)
- Indications Bipolar depression; Bipolar I disorders
- Focus Therapeutic Use
- 12 Jul 2024 Planned End Date changed from 31 Mar 2025 to 1 Oct 2025.
- 12 Jul 2024 Planned primary completion date changed from 31 Mar 2025 to 1 Oct 2025.
- 12 Jul 2024 Planned initiation date changed from 31 Mar 2024 to 1 Oct 2024.